Disclosed is the use of a composition comprising: (a) a virus-like particle (VLP) with at least one first attachment site and (b) at least one antigen with at least one second attachment site wherein said at least one antigen comprises an IL-1 molecule and wherein (a) and (b) are linked through said at least one first and said at least one second attachment site, for the manufacture of a medicament for the treatment of diabetes.